Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.58 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.57 |
| ▸ | PYGL | P06737 | 12/20 | 0.54 |
| ▸ | CYP51A1 | Q16850 | 3/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | PYGM | P11217 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17149920 | 0.91 | PYGL (0.58) | SMYD3PYGLCYP51A1EGFR | |
| SCHEMBL18750634 | 0.86 | PYGL (0.53) | SMYD3PYGLCYP51A1EGFR | |
| SCHEMBL17149903 | 0.78 | PYGL (0.63) | PYGLEGFR | |
| SCHEMBL17149617 | 0.78 | PYGL (0.63) | PYGLEGFR | |
| SCHEMBL17149864 | 0.78 | PYGL (0.63) | PYGLEGFR | |
| SCHEMBL17149647 | 0.77 | PYGL (0.65) | PYGLEGFR | |
| SCHEMBL17149853 | 0.77 | PYGL (0.65) | PYGLEGFR | |
| Hydrochloric Acid SCHEMBL5891475 | 0.77 | CYP51A1 (0.79) | PYGLCYP51A1PYGM | |
| SCHEMBL18766997 | 0.76 | PYGL (0.51) | SMYD3PYGLCYP51A1EGFR | |
| SCHEMBL18750660 | 0.76 | SMYD3 (0.60) | HRH4HRH3SMYD3PYGLCYP51A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858319-B2 | Indole derivatives for use in medicine | IOMET PHARMA LTD. (GB) | 2020-12-08 | — | — | US | disclosed |
| US-20190084933-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD. (GB) | 2019-03-21 | — | — | US | disclosed |
| US-10167257-B2 | Indole derivatives for use in medicine | IOMET PHARMA LTD. (GB) | 2019-01-01 | — | — | US | disclosed |
| US-20170107178-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD. (GB) | 2017-04-20 | — | — | US | disclosed |
| US-20170107178-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD. (GB) | 2017-04-20 | — | — | US | disclosed |
| WO-2015150097-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD (GB) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858319-B2 | Indole derivatives for use in medicine | IDO1, IDO2, TDO2 | HRH4 64/4885HRH3 111/4885SMYD3 1984/4885 |
| US-10167257-B2 | Indole derivatives for use in medicine | IDO1, IDO2, TDO2 | HRH4 67/4885HRH3 111/4885SMYD3 1961/4885 |
| US-20170107178-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IDO1, IDO2, TDO2 | HRH4 67/4885HRH3 111/4885SMYD3 1961/4885 |
| US-20190084933-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IDO1, IDO2, TDO2 | HRH4 72/4885HRH3 128/4885SMYD3 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.